Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's disease

Update Il y a 4 ans
Reference: EUCTR2013-004766-34

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare the complete response rate at the end of the 8-week period of randomized withdrawal (Week 34) between patients randomized to continued LCI699 therapy vs. placebo.


Inclusion criteria

  • Cushing's disease